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Early detection and management of pancreatic insufficiency is essential to optimize health and outcomes in cystic fibrosis patients. The
gold standard measures for assessment of pancreatic function are direct pancreatic stimulation tests, which have numerous limitations.
Estimation of fecal elastase-1 level to determine pancreatic function is an attractive alternative as the test is simple, rapid, cost-effective and
easy to perform even in children. This review summarizes the data from studies reflecting the validity, limitation and advantages of fecal
elastase-1 in assessing pancreatic function in cystic fibrosis patients.
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Cystic fibrosis (CF) is an autosomal recessive disorder
affecting about 30,000 patients in the United States. It is
caused by a mutation in the CF gene located on the long arm1569-1993/$ - see front matter D 2006 European Cystic Fibrosis Society. Publish
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E-mail address: ameet.daftary@cchmc.org (A. Daftary).of chromosome 7, which codes for the cystic fibrosis
transmembrane conductance regulator (CFTR) protein. The
most common and prevalent mutation is DF508 [1,2]. A
lack of the protein or its function results in mucous of
abnormally increased viscosity, which blocks the ducts of
exocrine glands, notably in the lungs and pancreas, with
eventual organ dysfunction. About 85% to 90% of CF
patients reportedly have pancreatic insufficiency [3]. Loss of
exocrine pancreatic function results in nutrient maldigestion
with secondary malnutrition. There is a negative correlation
of the degree of malnutrition with lung function, clinicals 5 (2006) 71 – 76ed by Elsevier B.V. All rights reserved.
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and accurately determine pancreatic insufficiency in patients
with CF and treat maldigestion to optimize their nutritional
status. The gold standard for estimation of pancreatic
function has been the direct pancreatic stimulation test,
such as the secretin–pancreozymin test. It is invasive
(involves duodenal intubation and intravenous injection of
pancreatic stimulant), time consuming, uncomfortable (of-
ten requiring conscious sedation in children), non-standard-
ized and expensive. Further, it is available at only academic
medical centers. Indirect pancreatic function tests include
three main categories of tests:
1. Assessment of absorption markers (e.g. NBT-PABA test/
Pancreolauryl test): these tests require withholding
enzyme supplements and are invasive.
2. Analysis of undigested/unabsorbed ingested nutrients
(e.g. quantitative fecal fat test): its use is limited by the
difficulty of completing a 72-h fecal collection (espe-
cially in young children), maintenance of adequate
dietary records and lack of specificity as a measure of
pancreatic insufficiency.
3. Measurement of pancreatic enzymes in serum or stool.
Serum enzymes provide poor quantitative estimation of
residual pancreatic function. The fecal tests such as the
estimation of fecal elastase-1 (E1) are easy to perform,
non-invasive and better reflect functional adequacy of the
enzyme.
An excellent overview of the general approach to
indirect pancreatic function testing in children has been
recently published and reviews the different methods in
detail [6].
Pancreatic elastase-1 was first described by Balo and
Banga in 1950 [7]. It is a pancreas specific carboxyendo-
peptidase, which catalyzes the hydrolysis of native elastin.
Quantitative estimation studies using immunoelectropho-
resis have shown that the enzyme is not significantly
degraded during intestinal transit. It is concentrated five-
to six-fold in feces compared to pancreatic-duodenal juice
and remains stable in stool at room temperature for up to 1
week [8–10]. There is significant correlation between
fecal and duodenal elastase concentration and duodenal
lipase, amylase, trypsin and bicarbonate concentration [11].
Thus, E1 levels reflect the levels of other pancreatic
enzymes. The cost of the reagent in microplate format is
under 20 euros and results can be available in less than
3 h, making this also a cost-effective and time saving
alternative to direct pancreatic stimulation tests. Using E1
levels as a bio-indicator of pancreatic function is an
attractive alternative to the gold standard, provocative
pancreatic stimulation with collection of duodenal secre-
tion. Presented is a review of the literature for studies
determining the validity, reliability and utility of E1 to
help conclude its place in managing pancreatic insuffi-
ciency in CF.2. Test characteristics
2.1. Sensitivity and specificity
E1 has been well characterized as a bio-indicator of
pancreatic insufficiency using the ELISA method. Loser et
al. studied patients with various degrees of chronic
pancreatic insufficiency comparing their secretin cerulein
test results with E1 levels [11]. They found that, using a
<200 Ag/g cut-off, the test had an overall 93% sensitivity
and 93% specificity. Limits of analytical sensitivity are not
well defined, but a detection limit of 15 Ag/g is generally
reported [12]. Soldan et al. compared 16 CF patients with
established pancreatic insufficiency by the secretin–pancre-
ozymin test to 23 healthy controls and found that, using the
standard cut-off of 200 Ag/g of stool for E1, they had a 96%
specificity and 100% sensitivity for detection of pancreatic
insufficiency [13]. An important consideration for this study
was that all their patients had moderate to severe pancreatic
insufficiency. Walkowiak et al. studied the sensitivity of E1
compared to secretin–cholecystokinin (SCCK) test and
quantitative fecal fat excretion in 28 patients with an age
range of 4–20 years [14]. Based on the SCCK test, patients
were classified as mildly, moderately or severely pancreatic
insufficient. The sensitivity of E1 for the moderate and severe
subgroups was 100%, but in the mild subgroup was only 25%
with specificity of 96.4%. This study highlighted an
important point that the test has high sensitivity for moderate
to severe pancreatic insufficiency but not for mild cases.
Using linear regression analysis, this study confirmed high
correlation between E1 and duodenal volume, bicarbonate,
amylase, lipase and trypsin secretion (in all cases, P <0.001).
2.2. Test variability
As with any test, interpretation requires knowledge of
test variability. In a study by Phillips et al., E1 levels were
determined from stool samples provided on 3 consecutive
days by 20 adults without symptomatic pancreatic insuffi-
ciency [15]. The mean value was 457 Ag/g (124–1683) with
an intra-assay variation of 6.4% and inter-assay variation of
8.8%. The mean intra-patient variation was 17%. Similar
intra-assay (5.8%) and inter-assay (7.7%) variances were
reported by Loser et al. [11]. Hamwi et al. studied eight
patients to determine the variation in E1 determination
within one stool sample and samples from 40 patients
collected on 3 consecutive days for day to day variation
[16]. They found considerable variation in E1 concentra-
tions within one stool passage (mean CV: 22%, range 4.6–
83.1%) and from day to day (mean CV: 26%, range 2.4–
61.1%). Thus, they recommended that more than one stool
sample per individual should be analyzed and the samples
should be collected on different days. Furthermore, they
found that a value T% around the cut-off of 200 Ag/g may
still reflect normal pancreatic function. Loser et al. evaluated
eight of their chronic pancreatic insufficient patients for E1
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[11]. They compared E1 concentrations between stool
samples stored for a week at different temperatures. A
variation of 6.64% between samples stored at 25 -C and
room temperature was noted and 2.51% for samples stored
at 4 -C and room temperature. To determine test variability
in CF patients, Meyts et al. recruited 26 patients [17]. Based
on symptoms and a 72-h fecal fat estimation, 19 patients
were determined to be pancreatic insufficient. Stool samples
were collected from these patients on 7 consecutive days.
The mean intra-assay variability was 4.06%. All pancreatic
insufficient patients had E1 levels below the detection limit
of the test. In patients with pancreatic sufficiency, the
maximal intra-patient variability was 35%, with one stool
sample E1 level below 200 Ag/g. For patients with
symptoms of pancreatic insufficiency but normal fecal fat
estimation, the maximal intra-patient variability was 37%
and E1 levels were inconclusive for the diagnosis of
pancreatic insufficiency. Limitations of this study were
small patient numbers and comparison of E1 with fecal fat
estimation, not the gold standard (direct pancreatic stimu-
lation test). It can be surmised that there is a significant
variation in E1 levels within a single as well as between
multiple stool samples from a single individual. This wide
variation could be explained by the small patient numbers in
these studies; however, the degree of variability may not be
clinically significant in patients with moderate to severe
pancreatic insufficiency usually seen in CF. The difficulty in
interpreting borderline E1 levels is the most problematic and
several stool samples may need to be analyzed to facilitate a
decision regarding pancreatic insufficiency.
2.3. Limitations of E1
Though monoclonal ELISA appears to be more com-
monly used, both polyclonal and monoclonal ELISA
methods of E1 estimation have shown statistically significant
differences between patients with normal pancreatic function
and pancreatic insufficiency [18]. Hardt et al. showed that
the polyclonal antibodies react with some as yet unknown
antigen associated with elastase. Falsely elevated E1 levels
may be detected when using the polyclonal antibody test
even in the presence of clinical steatorrhea [19,20]. Care
should be taken in interpreting values from diarrheal stools
and in the presence of intestinal inflammation or enteropathy
as underestimation of true E1 levels may result [21–26].
Intestinal inflammation can cause low enzyme levels, which
may take several months to recover [23]. An important
limitation of E1 is its inability to distinguish primary
exocrine pancreatic insufficiency from exocrine insufficien-
cy secondary to intestinal villous damage.
2.4. Determining cut-off values
It was important to determine whether the standard cut-
off values established in a broad group of pancreaticinsufficient patients could be extrapolated to CF patients.
Beharry et al. compared 57 pancreatic sufficient patients
who had normal fecal fat study results with 50 who had
pancreatic insufficiency (78% had CF) and 28 with
pancreatic disease but phenotypically pancreatic sufficient
[27]. They found that a 100 Ag/g cut-off had a 99%
predictive value for pancreatic insufficiency. They further
corroborated the 200 Ag/g cut-off for pancreatic sufficiency.
Walkowiak compared 91 CF patients with 70 healthy
subjects and 70 non-CF pancreatic insufficient patients
[28]. The aim was to determine the sensitivity and
specificity of E1 in assessing pancreatic exocrine function
in children as well as to study the distribution of enzyme
levels. The study found a median E1 of 10 Ag/g (0–300) in
CF pancreatic insufficient and 218 Ag/g (87–629) in CF
pancreatic sufficient patients. Using a cut-off value of 200
Ag/g, E1 had a 98.7% sensitivity in detecting CF pancreatic
insufficient patients. In the CF pancreatic sufficient group,
however, the test sensitivity was only 50%. Cade et al.
described the E1 status of 142 patients from a large CF
clinic [29]. One hundred and thirty-five patients were
pancreatic insufficient with a median E1 of 10 Ag/g (2–
33) and seven were pancreatic sufficient with a median E1
of 698 Ag/g (400.5–824.5). There were 85 non-CF control
subjects in the study with a median E1 of 615 Ag/g (420–
773). In a multinational European study, 725 CF patients
and 243 healthy subjects had stool E1 levels determined
with the objective of defining appropriate cut-off values for
normal [30]. Significant inter-country differences in E1
values for normal healthy subjects were noted. E1 levels in
DF508 homozygotes were however very similar across the
nations. Based on this study, the best cut-off between CF
pancreatic insufficient and normal function was 184 Ag/g, but
the authors recommended using a range of 160–200 Ag/g
because of different distributions of pancreatic function in
different countries and that individual nations should
establish their own cut-offs for normal.
There was also concern whether the adult cut-off values
could be generalized across all age groups. The results of a
study of 148 infants without known bowel or pancreatic
disorders showed that 96.8% of neonates had E1 levels
above the 200 Ag/g cut-off by 2 weeks of age, independent
of gestational age [31]. Pre-term babies had levels under
30 Ag/g up to 48 h after birth but 43% of term infants had
normal adult values within 48 h of life. It thus appears that
E1 reaches adult levels by 2 weeks of age and may be used
for screening pancreatic function in CF patients who are
born with insufficiency.
2.5. Genotype–phenotype correlation
In a study to evaluate the correlation of genotype with
pancreatic insufficiency in CF patients, E1 concentrations
were measured in 394 CF patients and 105 healthy controls
[32]. It was found that patients who carried DF508,
N1303K, CFTR del 2,3(21 kb), G542X, 1717-1G-A,
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DI507, G551D or 895T mutations in any combination were
associated with severe pancreatic insufficiency and low E1
levels. Hence, these mutations were described as Fsevere
mutations_. High E1 levels and pancreatic sufficiency
correlated with the presence of at least one of the following
mutations: R117H, 3171insC, A155P2, 138insL, 296+1G-
A, E92GK, E217G, 2789+5G-A, 3849+1 kbC-T/3849+1
kbC-T. However, the combinations of DF508/3849+10
kbC-T, 1717-1GA/3849+10 kbC-T and DF508/R334 W
were associated with high and low E1 levels. The authors
thus concluded that the presence of two severe mutations
was associated with pancreatic insufficiency; the presence of
at least one mild mutation correlated with a pancreatic
sufficient phenotype; however, this is variable. Cade et al.
demonstrated in their study that 93 CF patients were
homozygous for the DF508 mutation and 38 were hetero-
zygous for this mutation [29]. The median E1 for
homozygous DF508 pancreatic insufficient patients was
10 Ag/g and for the heterozygous pancreatic insufficient CF
patients was 12 Ag/g confirming that the DF508 genotype
usually correlates with a pancreatic insufficient phenotype.
Knowledge of E1 level correlation with genotype is useful
for clinicians when counseling newly diagnosed CF patients
for prognosis as genotype data is often not immediately
available.
2.6. Comparison with fecal chymotrypsin
A strong contender to E1 estimation by ELISA is fecal
chymotrypsin assessment; for ease, simplicity and cost-
effectiveness of the latter test. Carroccio et al. in a
multicenter study compared 49 CF patients (median age 5
years) with 45 controls (median age 5 years) and found no
significant difference between the sensitivity of E1 and fecal
chymotrypsin in the assessment of pancreatic maldigestion
[33]. They used a cut-off of 7.5 U/g of stool and limitations
of their study were that all patients had a significant degree
of pancreatic insufficiency with 26 CF patients being
continued on enzyme supplementation. In a study of 123
CF patients, Walkowiak et al. showed that, using a cut-off
level of 3 U/g for chymotrypsin, E1 had a higher sensitivity
(90.2% vs. 81.3%) in detecting moderate to severe
steatorrhea [34]. In the presence of mild steatorrhea, the
sensitivity of E1 was estimated at 69.2%, whereas that of
fecal chymotrypsin was 41%. When cut-off levels of 6 U/g
were used in the same study, the sensitivities were identical
between E1 and fecal chymotrypsin; however, the specific-
ity of E1 was 98.1%, whereas that of fecal chymotrypsin
was 90.5% (P <0.014). Brown et al., in a study of 30
children, showed good correlation of mean 72-h fecal
chymotrypsin levels with the level induced during a direct
pancreatic stimulation test. However, chymotrypsin levels
from individual stool samples correlated poorly with direct
pancreatic stimulation test results [35]. Another limitation of
chymotrypsin is that being a constituent of pancreaticenzyme supplements, since the assay cannot distinguish
exogenous from endogenous chymotrypsin; patients must
be off supplements prior to stool collection for fecal
chymotrypsin assay. Thus, E1 appears to have some
advantages over fecal chymotrypsin in detection of pancre-
atic insufficiency in that it has comparable if not better
sensitivity, depending on the cut-off values used. E1 is very
stable in stool samples and can be estimated even in patients
on pancreatic enzyme supplements without need for their
discontinuation [12].
2.7. Longitudinal follow up of exocrine pancreatic function
in CF using E1
Walkowiak et al. serially studied E1 on 28 patients with
CF diagnosed via neonatal screening [36]. E1 levels along
with fecal fat balance studies were performed at diagnosis
and then at 6-month intervals up to 12 months of age. All
patients had severe mutations. By 3–4 months of age, all
patients had E1 levels <200 Ag/g and 81.5% had steator-
rhea. At 6 months of age, all patients had levels <100 Ag/g
and, by 12 months, all the children were insufficient, which
was the clinical endpoint of the study. In a review on the
detection and follow up of exocrine pancreatic insufficiency
in cystic fibrosis, Leus et al. have evaluated E1 for neonatal
screening for pancreatic insufficiency in CF as well as in the
longitudinal follow up of pancreatic function [37]. They
recommend that, once patients are on enzyme supplements,
the 13 C mixed triglyceride breath test and acid steatocrit
test give more clinical information in determining adequacy
of supplementation as these tests reflect the adequacy of
total-endogenous and exogenous enzyme function. E1, on
the other hand, can only provide information on endogenous
enzyme activity. It has been estimated that about 10–15% of
CF patients are pancreatic sufficient [2] and hence may not
require enzyme supplementation. Borowitz et al., in a
multicentric study involving 1215 patients, found 1050
were correctly classified pancreatic insufficient based on E1
levels [38]. In the study, 141 subjects had E1 levels >200
Ag/g and 81 of these were on pancreatic enzyme supple-
ments, suggesting they could have been treated unnecessar-
ily. In a follow up study, Cohen et al. found that 12% of CF
patients had been misclassified pancreatic insufficient [39].
E1 will help distinguish the patients with true pancreatic
insufficiency as well as facilitate determining when enzyme
supplementation becomes necessary. Considering the annual
average expense of US$13,300 per CF patient [40],
refraining from administering unnecessary medication
would be a very valuable economic advantage to the health
system.3. Conclusion
E1 is a rapid, relatively inexpensive diagnostic test with
good sensitivity and specificity for detection of pancreatic
A. Daftary et al. / Journal of Cystic Fibrosis 5 (2006) 71–76 75insufficiency as compared to direct pancreatic stimulation
tests. As it uses an ELISA method, it has the potential for
wide acceptance in clinical laboratories. After 2 weeks of
age, standard cut-off values may be used; thus, on account
of high sensitivity and specificity E1 can be a useful
neonatal screening test for pancreatic insufficiency in CF
patients. With the increasing use of CF neonatal screening,
E1 would allow for earlier detection and management of
pancreatic insufficiency in this population thereby con-
tributing to improved disease outcomes. E1 can be
estimated in CF patients already on pancreatic enzyme
supplements and still reliably detect pancreatic insufficien-
cy due to the lack of cross reactivity between human and
animal E1. The test can also be used in the longitudinal
follow up of pancreatic function in CF patients. Results of
the test should be interpreted with caution when they are
in the borderline range owing to the high coefficient of
variation of the test and normal variations between
populations. However, even with the described degree of
variation, it is unlikely to significantly impact clinical
interpretation in overtly insufficient patients. The test is
not useful for estimating the adequacy of pancreatic
enzyme supplementation as it reflects quantitative pancre-
atic function and not net effect of enzyme performance.
Lastly, bearing in mind that E1 cannot distinguish primary
from secondary pancreatic exocrine insufficiency is
important. Values can be underestimated in diluted stool
samples or in the presence of intestinal inflammation/
enteropathy and may be take several months to normalize.
Considering the limitations of direct and other indirect
pancreatic function tests, E1 is an attractive alternative for
the detection and follow up of pancreatic insufficiency in
CF patients.References
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